Mitochondrial modulation to improve metabolic syndrome during aging
US-2022281902-A1 · Sep 8, 2022 · US
US9416149B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9416149-B2 |
| Application number | US-201414262448-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 25, 2014 |
| Priority date | Apr 25, 2013 |
| Publication date | Aug 16, 2016 |
| Grant date | Aug 16, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides methods for treating fibrosis, as well as methods for modulating mitochondrial peroxide production in a cell, and methods for modulating the import of Rac1 into the mitochondria of a cell.
Opening claim text (preview).
What is claimed is: 1. A method to treat pulmonary fibrosis in an animal in need thereof comprising administering to the animal an effective amount of a compound of formula I, formula II or formula III: wherein: R 1 is a saturated or unsaturated (C 5 -C 20 )alkyl chain that optionally comprises one or more aryl rings in the chain and that is optionally substituted with one or more halo, trifluoromethyl, —OR a , —P(═O)(OR a ) 2 , or —NR b R c ; R 2 is a saturated or unsaturated (C 5 -C 20 )alkyl chain that optionally comprises one or more aryl rings in the chain and that is optionally substituted with one or more halo, trifluoromethyl, —OR a , —P(═O)(OR a ) 2 , or —NR b R c ; each R 3 , R 4 , R 5 , and R 6 is independently OH or (C 1 -C 6 )alkoxy; each R a is independently H, (C 1 -C 6 )alkyl, or aryl; and each R b and R c is independently H, (C 1 -C 6 )alkyl, or aryl; or R b and R c together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring; wherein any aryl of R 1 , R 2 , R a , R b or R c is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR d R e or S(O) 2 NR d R e , wherein each R d and R e is independently H or (C 1 -C 6 )alkyl; X is (C 1 -C 6 )alkyl; Y is (C 1 -C 6 )alkyl; R 7 is a saturated or unsaturated (C 1 -C 20 )alkyl chain that optionally comprises one or more aryl or heteroaryl rings in the chain wherein (C 1 -C 20 )alkyl is optionally substituted with one or more halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, NR m R n or S(O) 2 NR p R q and wherein any aryl or heteroaryl is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR a1 R b1 , or S(O) 2 NR c1 R d1 ; R 8 is H or a saturated or unsaturated (C 1 -C 20 )alkyl chain that optionally comprises one or more aryl or heteroaryl rings in the chain wherein (C 1 -C 20 )alkyl is optionally substituted with one or more halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, NR m R n , or S(O) 2 NR p R q and wherein any aryl or heteroaryl is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR a1 R b1 , or S(O) 2 NR c1 R d1 ; each R 9 , R 10 , R 11 , and R 12 is independently OH or (C 1 -C 6 )alkoxy; R 13 is a saturated or unsaturated (C 1 -C 20 )alkyl chain that optionally comprises one or more aryl or heteroaryl rings in the chain wherein (C 1 -C 20 )alkyl is optionally substituted with one or more halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, NR m R n , or S(O) 2 NR p R q and wherein any aryl or heteroaryl is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR a1 R b1 , aryl, heteroaryl, or S(O) 2 NR c1 R d1 ; R 14 is a saturated or unsaturated (C 1 -C 20 )alkyl chain that optionally comprises one or more aryl or heteroaryl rings in the chain wherein (C 1 -C 20 )alkyl is optionally substituted with one or more halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, NR m R n , or S(O) 2 NR p R q and wherein any aryl or heteroaryl is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR a1 R b1 , aryl, heteroaryl, or S(O) 2 NR c1 R d1 ; R 15 is a saturated or unsaturated (C 1 -C 20 )alkyl chain that optionally comprises one or more aryl or heteroaryl rings in the chain wherein (C 1 -C 20 )alkyl is optionally substituted with one or more halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, NR m R n , or S(O) 2 NR p R q and wherein any aryl or heteroaryl is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR a1 R b1 , or S(O) 2 NR c1 R d1 ; R 16 is H or a saturated or unsaturated (C 1 -C 20 )alkyl chain that optionally comprises one or more aryl or heteroaryl rings in the chain wherein (C 1 -C 20 )alkyl is optionally substituted with one or more halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, NR m R n , or S(O) 2 NR p R q and wherein any aryl or heteroaryl is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR a1 R b1 , or S(O) 2 NR c1 R d1 ; each R a1 and R b1 is independently H, (C 1 -C 6 )alkyl, or aryl; or R a1 and R b1 together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring; each R c1 and R d1 is independently H, (C 1 -C 6 )alkyl, or aryl; or R c1 and R d1 together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring; each R p and R q is independently H, (C 1 -C 6 )alkyl, or aryl; or R p and R q together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring; each R p and R q is independently H, (C 1 -C 6 )alkyl, or aryl; or R p and R q together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring; and wherein any aryl of R a1 , R b1 , R c1 , R d1 , R m , R n , R p or R q is optionally substituted with one or more (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR s R t , or S(O) 2 NR s R t wherein each R s and R t is independently H or (C 1 -C 6 )alkyl; or a pharmaceutically acceptable salt or prodrug thereof. 2. The method of claim 1 , comprising administering to the animal a compound of formula I: or a pharmaceutically acceptable salt or prodrug thereof. 3. The method of claim 1 , wherein R 1 is of the formula, wherein: n is 0, 1, or 2; and R g and R h together with the atoms to which they are attached form an aryl ring that is optionally substituted with one or more (e.g. 1, 2, 3, or 4) (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, halo, cyano, nitro, carboxy, trifluoromethyl, trifluoromethoxy, NR d R e , or S(O) 2 NR d R e , wherein each R d and R e is independently H or (C 1 -C 6 )alkyl. 4. The method of claim 1 , wherein R 1 is of the formula, wherein: n is 0, 1, 2, or 3; each bond designated by ----- is independently either present or is absent; and R b is phenyl or naphthyl and is optionally substituted with one or more carboxy or S(O) 2 NR d R
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid · CPC title
having the two nitrogen atoms in positions 1 and 3 · CPC title
Five-membered rings · CPC title
Polyphosphonic acids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.